Advertisement

Molecular Medicine

, Volume 17, Issue 5–6, pp 434–441 | Cite as

Targeting Inflammation in Heart Failure with Histone Deacetylase Inhibitors

  • Timothy A McKinsey
Review Article

Abstract

Cardiovascular insults such as myocardial infarction and chronic hypertension can trigger the heart to undergo a remodeling process characterized by myocyte hypertrophy, myocyte death and fibrosis, often resulting in impaired cardiac function and heart failure. Pathological cardiac remodeling is associated with inflammation, and therapeutic approaches targeting inflammatory cascades have shown promise in patients with heart failure. Small molecule histone deacetylase (HDAC) inhibitors block adverse cardiac remodeling in animal models, suggesting unforeseen potential for this class of compounds for the treatment of heart failure. In addition to their beneficial effects on myocardial cells, HDAC inhibitors have potent antiinflammatory actions. This review highlights the roles of HDACs in the heart and the potential for using HDAC inhibitors as broad-based immunomodulators for the treatment of human heart failure.

Notes

Acknowledgments

I thank MA Cavasin and DD Lemon for helpful discussions.

References

  1. 1.
    Lloyd-Jones D, et al. (2009) Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 119:480–6.CrossRefGoogle Scholar
  2. 2.
    Deswal A, et al. (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 103:2055–9.CrossRefGoogle Scholar
  3. 3.
    Levine B, Kalman J, Mayer L, Fillit HM, Packer M. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323:236–41.CrossRefGoogle Scholar
  4. 4.
    Rauchhaus M, et al. (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 102:3060–7.CrossRefGoogle Scholar
  5. 5.
    Bozkurt B, Mann DL, Deswal A. (2010) Biomark- ers of inflammation in heart failure. Heart Fail. Rev. 15:331–41.CrossRefGoogle Scholar
  6. 6.
    Schindler R, Dinarello CA, Koch KM. (1995) Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine. 7:526–33.CrossRefGoogle Scholar
  7. 7.
    Abbate A, et al. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 117:2670–83.CrossRefGoogle Scholar
  8. 8.
    Bujak M, et al. (2008) Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am. J. Pathol. 173:57–67.CrossRefGoogle Scholar
  9. 9.
    Abbate A, et al. (2010) Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am. J. Cardiol. 105:1371–7.CrossRefGoogle Scholar
  10. 10.
    Bozkurt B, et al. (2001) Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 103:1044–7.CrossRefGoogle Scholar
  11. 11.
    Deswal A, et al. (1999) Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 99:3224–6.CrossRefGoogle Scholar
  12. 12.
    Mann DL, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 109:1594–602.CrossRefGoogle Scholar
  13. 13.
    Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 107:3133–40.CrossRefGoogle Scholar
  14. 14.
    Burchfield JS, et al. (2010) The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ. Heart Fail. 3:157–64.CrossRefGoogle Scholar
  15. 15.
    Yang XJ, Seto E. (2008) Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell. 31:449–61.CrossRefGoogle Scholar
  16. 16.
    Gregoretti IV, Lee YM, Goodson HV. (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338:17–31.CrossRefGoogle Scholar
  17. 17.
    McKinsey TA, Zhang CL, Olson EN. (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27:40–7.CrossRefGoogle Scholar
  18. 18.
    Devereux RB, et al. (2004) Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 292:2350–6.CrossRefGoogle Scholar
  19. 19.
    Gardin JM, Lauer MS. (2004) Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 292:2396–8.CrossRefGoogle Scholar
  20. 20.
    Han A, et al. (2003) Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2. Nature. 422:730–4.CrossRefGoogle Scholar
  21. 21.
    Han A, He J, Wu Y, Liu JO, Chen L. (2005) Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. J. Mol. Biol. 345:91–102.CrossRefGoogle Scholar
  22. 22.
    Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN. (2006) CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J. Clin. Invest. 116:1853–64.CrossRefGoogle Scholar
  23. 23.
    Bush E, et al. (2004) A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 101:2870–5.CrossRefGoogle Scholar
  24. 24.
    Vega RB, et al. (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell. Biol. 24:8374–85.CrossRefGoogle Scholar
  25. 25.
    Zhang CL, et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:479–88.CrossRefGoogle Scholar
  26. 26.
    Chang S, et al. (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 24:8467–76.CrossRefGoogle Scholar
  27. 27.
    Antos CL, et al. (2003) Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 278:28930–7.CrossRefGoogle Scholar
  28. 28.
    Bradner JE, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6:238–43.CrossRefGoogle Scholar
  29. 29.
    Heltweg B, et al. (2004) Subtype selective substrates for histone deacetylases. J. Med. Chem. 47:5235–43.CrossRefGoogle Scholar
  30. 30.
    Marks PA, Breslow R. (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25:84–90.CrossRefGoogle Scholar
  31. 31.
    Kook H, et al. (2003) Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Invest. 112:863–71.CrossRefGoogle Scholar
  32. 32.
    Kee HJ, et al. (2006) Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 113:51–9.CrossRefGoogle Scholar
  33. 33.
    Liu F, et al. (2008) Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J. Mol. Cell Cardiol. 45:715–23.CrossRefGoogle Scholar
  34. 34.
    Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 64:1079–86.CrossRefGoogle Scholar
  35. 35.
    Matalon S, et al. (2010) The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1–9.CrossRefGoogle Scholar
  36. 36.
    Terbach N, Williams RS. (2009) Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 37:1126–32.CrossRefGoogle Scholar
  37. 37.
    Kong Y, et al. (2006) Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation. 113:2579–88.CrossRefGoogle Scholar
  38. 38.
    Granger A, et al. (2008) Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 22:3549–60.CrossRefGoogle Scholar
  39. 39.
    Lee TM, Lin MS, Chang NC. (2007) Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am. J. Physiol. Heart Circ. Physiol. 293:H968–77.CrossRefGoogle Scholar
  40. 40.
    Zhang LX, et al. (2010) Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am. J. Physiol. Heart Circ. Physiol. 298:H2154–63.CrossRefGoogle Scholar
  41. 41.
    Zhao TC, Cheng G, Zhang LX, Tseng YT, Padbury JF. (2007) Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc. Res. 76:473–81.CrossRefGoogle Scholar
  42. 42.
    Cardinale JP, et al. (2010) HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension. 56:437–44.CrossRefGoogle Scholar
  43. 43.
    Iyer A, et al. (2010) Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br. J. Pharmacol. 159:1408–17.CrossRefGoogle Scholar
  44. 44.
    Cho YK, et al. (2010) Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ. J. 74:760–70.CrossRefGoogle Scholar
  45. 45.
    Voelkel NF, et al. (2006) Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 114:1883–91.CrossRefGoogle Scholar
  46. 46.
    Kee HJ, et al. (2008) Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ. Res. 103:1259–69.CrossRefGoogle Scholar
  47. 47.
    Trivedi CM, et al. (2007) Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat. Med. 13:324–31.CrossRefGoogle Scholar
  48. 48.
    Haberland M, Montgomery RL, Olson EN. (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10:32–42.CrossRefGoogle Scholar
  49. 49.
    Montgomery RL, et al. (2007) Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes. Dev. 21:1790–802.CrossRefGoogle Scholar
  50. 50.
    Gallo P, et al. (2008) Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc. Res. 80:416–24.CrossRefGoogle Scholar
  51. 51.
    Bush EW, McKinsey TA. (2010) Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ. Res. 106:272–84.CrossRefGoogle Scholar
  52. 52.
    Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med 13:1299–307.CrossRefGoogle Scholar
  53. 53.
    Wang L, de Zoeten EF, Greene MI, Hancock WW. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.. Nat. Rev. Drug. Discov. 8:969–81.CrossRefGoogle Scholar
  54. 54.
    Littman DR, Rudensky AY. (2010) Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 140:845–58.CrossRefGoogle Scholar
  55. 55.
    Saouaf SJ, et al. (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87:99–104.CrossRefGoogle Scholar
  56. 56.
    de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 138:583–94.CrossRefGoogle Scholar
  57. 57.
    Tang TT, et al. (2010) Defective circulating CD4CD25+Foxp3+CD127(low) regulatory T-cells in patients with chronic heart failure. Cell Physiol. Biochem. 25:451–8.CrossRefGoogle Scholar
  58. 58.
    Kvakan H, et al. (2009) Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 119:2904–12.CrossRefGoogle Scholar
  59. 59.
    Kee HJ, Kook H. (2009) Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J. Mol. Cell Cardiol. 47:770–80.CrossRefGoogle Scholar
  60. 60.
    Liao X, et al. (2010) Kruppel-like factor 4 regulates pressure-induced cardiac hypertrophy. J. Mol. Cell Cardiol. 49:334–8.CrossRefGoogle Scholar
  61. 61.
    Gupta MP, Samant SA, Smith SH, Shroff SG. (2008) HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity. J. Biol. Chem. 283:10135–46.CrossRefGoogle Scholar
  62. 62.
    Brown RD, Ambler SK, Mitchell MD, Long CS. (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 45:657–87.CrossRefGoogle Scholar
  63. 63.
    Porter KE, Turner NA. (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 123:255–78.CrossRefGoogle Scholar
  64. 64.
    Barter MJ, et al. (2010) HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biol. 29:602–12.CrossRefGoogle Scholar
  65. 65.
    Yoshikawa M, Hishikawa K, Idei M, Fujita T. (2010) Trichostatin a prevents TGF-beta1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells. Eur. J. Pharmacol. 642:28–36.CrossRefGoogle Scholar
  66. 66.
    Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA. (2009) Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition.. Am. J. Physiol. Lung Cell Mol. Physiol. 297:L864–70.CrossRefGoogle Scholar
  67. 67.
    Zeisberg EM, et al. (2007) Endothelial-to-mes-enchymal transition contributes to cardiac fibrosis. Nat. Med. 13:952–61.CrossRefGoogle Scholar
  68. 68.
    Weiskirchen R, etal. (2009) BMP-7 as antagonist of organ fibrosis. Front Biosci. 14:4992–5012.CrossRefGoogle Scholar
  69. 69.
    Widyantoro B, et al. (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation. 121:2407–18.CrossRefGoogle Scholar
  70. 70.
    Peinado H, Ballestar E, Esteller M, Cano A. (2004) Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol. Cell. Biol. 24:306–19.CrossRefGoogle Scholar
  71. 71.
    Borlaug BA, Kass DA. (2006) Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc. Med. 16:273–9.CrossRefGoogle Scholar
  72. 72.
    Borlaug BA. (2009) Treatment of heart failure with preserved ejection fraction. Curr. Treat. Options Cardiovasc. Med. 11:79–87.CrossRefGoogle Scholar
  73. 73.
    Liang KP, et al. (2010) Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann. Rheum. Dis. 69:1665–70.CrossRefGoogle Scholar
  74. 74.
    Marks PA. (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs. 19:1049–66.CrossRefGoogle Scholar
  75. 75.
    Galli M, et al. (2010) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann. Hematol. 89:185–90.CrossRefGoogle Scholar
  76. 76.
    Giles F, et al. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 12:4628–35.CrossRefGoogle Scholar
  77. 77.
    Klimek VM, et al. (2008) Tolerability, pharmaco-dynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodys-plastic syndromes. Clin. Cancer Res. 14:826–32.CrossRefGoogle Scholar
  78. 78.
    O’Connor OA, et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoy-lanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24:166–73.CrossRefGoogle Scholar
  79. 79.
    Matsuoka H, et al. (2007) Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur. J. Pharmacol. 571:88–96.CrossRefGoogle Scholar
  80. 80.
    Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452–8.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  1. 1.Department of Medicine, Division of CardiologyUniversity of Colorado DenverAuroraUSA

Personalised recommendations